Sun Pharma FDA nod for Leqselvi as alopecia drug fight heats up against Pfizer and Eli Lilly

Published on 24 April 2026

A massive acquisition just unlocked US FDA approval

Sun Pharma’s big US bet is paying off. After spending over INR 4,688 crore to buy Concert Pharma, the company secured rights to Leqselvi for hair growth in alopecia areata patients. The drug has now received US FDA approval, but insiders say the real contest with global giants like Pfizer and Eli Lilly is only beginning.

Sun Pharma’s Concert Pharma deal priced in access to Leqselvi
Leqselvi has received US FDA approval for alopecia areata
The launch sets up direct competition with Pfizer and Eli Lilly
Investors will watch next steps after this US regulatory win

#acquisitions #fda approval #sun pharma #alopecia areata #pharmaceuticals

Read the full story at The Economic Times

This summarization was done by Beige for a story published on The Economic Times

Sun Pharma FDA nod for Leqselvi as alopecia drug fight heats up against Pfizer and Eli Lilly

The full experience is on mobile.